Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
Awakn Life Sciences Corp. (OTCQB:AWKNF), a company focused on the development of psychedelic therapeutics for addiction and mental health disorders, has announced an increase in the size of its ongoing private placement financing.
致力於開發用於藥物成癮和心理健康障礙的致幻治療方案的Awakn Life Sciences Corp.（OTCQB：AWKNF）宣佈增加其進行中的定向增發融資規模。
What Happened: Initially planned for $1 million, the offering has been expanded to $2 million, reflecting heightened investor interest and support. The company also confirmed the closing of the fourth tranche, securing an additional $394,286 through the sale of 857,143 units at $0.46 per unit, bringing the total funds raised to $1,117,142 so far.
最初計劃爲100萬美元的定向增發規模已擴大至200萬美元，反映出投資者興趣和支持的增加。該公司還確認了第四筆分期付款的完成，通過以0.46美元的價格出售857,143個單位，獲得了額外的394,286美元，使籌集的總資金達到1,117,142美元。
Each unit comprises one common share and 0.75 of a warrant, allowing holders to purchase an additional share at $0.63 within five years. Proceeds from the financing will be used to support Awakn's working capital needs as it advances its research and development, particularly focusing on its treatment for Alcohol Use Disorder (AUD).
每個單位由一股普通股和0.75個權證組成，允許持有人在五年內以0.63美元的價格購買一股額外的股票。融資所得將用於支持Awakn的營運資本需求，尤其是其酒精使用障礙（AUD）治療方案的研發工作。
Can CBD Help With Alcohol Use Disorder? New Scientific Review Finds There's Something To It
CBD對酒精使用障礙有幫助嗎？新的科學綜述發現其中有些東西
Why It Matters: AUD represents a significant market, with approximately 29 million affected adults in the U.S. and 40 million in key European markets. Awakn's CEO, Anthony Tennyson, highlighted the company's commitment to addressing this substantial unmet need, stating, "Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need."
爲什麼這很重要：AUD代表着一個巨大的市場，在美國約有2900萬受影響成年人，在歐洲的主要市場約有4000萬人。Awakn的首席執行官安東尼·坦尼森（Anthony Tennyson）強調了公司致力於解決這一重大未滿足需求的承諾，他說：「我們的目標是爲那些急需突破性治療方案的成癮者提供幫助。」
The securities issued are subject to a four-month hold period, in compliance with applicable securities regulations. Awakn has reaffirmed that this press release does not constitute an offer to sell securities in the U.S., and its securities have not been registered under the U.S. Securities Act of 1933.
根據適用的證券法規，所發行的證券將受到爲期四個月的限售期限制。Awakn重申，本新聞稿不構成在美國銷售證券的要約，其證券未在1933年美國證券法下注冊。
Now Read: Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
現在閱讀：致幻劑能夠結束狂飲嗎？一項突破性專利說是
譯文內容由第三人軟體翻譯。